Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term...
Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT Trial
About this item
Full title
Author / Creator
For the Protease Inhibitor monotherapy Versus Ongoing Triple therapy (PIVOT) Trial Team , Protease Inhibitor monotherapy Versus Ongoing Triple therapy (PIVOT) Trial Team , Oddershede, Lars , Walker, Simon , Stöhr, Wolfgang , Dunn, David T. , Arenas-Pinto, Alejandro , Paton, Nicholas I. and Sculpher, Mark
Publisher
Cham: Springer International Publishing
Journal title
Language
English
Formats
Publication information
Publisher
Cham: Springer International Publishing
Subjects
More information
Scope and Contents
Contents
Background
Protease inhibitor (PI) monotherapy can maintain virological suppression in the majority of patients once it has been established on triple therapy and may also have the potential for substantial cost savings arising from the use of fewer drugs. However, the cost effectiveness of PI monotherapy has yet to be demonstrated.
Objective...
Alternative Titles
Full title
Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT Trial
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1801429228
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1801429228
Other Identifiers
ISSN
1170-7690
E-ISSN
1179-2027
DOI
10.1007/s40273-016-0396-x
